---

---

therapeutics   tags : Positive   

save search

---

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K |

| Email alert Add to watchlist
acr-368 positive pipeline for program therapeutics today

---

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CAPR | $5.04 4.56% 4.37% 910K |

Health Technology

| 0.0% | O: 9.13% H: 7.41% C: -4.18%
cap-1002 fda positive program therapeutics duchenne type-b meeting

---

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K |

Professional, Scientific, and T...

| 0.0% | O: -0.29% H: 0.0% C: 0.0%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results

---

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CYTO | $1.495 -5.38% -5.69% 3M |

Manufacturing

| 0.0% | O: 1.27% H: 0.0% C: -10.0%
positive publication bentrio trial therapeutics results

---

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K |

Health Technology

| 0.97% | O: 0.77% H: 0.0% C: 0.0%
positive treatment global for

---

Calliditas Announces Positive NefIgArd Open Label Extension Results
Published: 2024-04-24 (Crawled : 08:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K |

Health Technology

| 0.0% | O: 3.46% H: 0.0% C: -1.75%
label positive nefigard extension results

---

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M |

Health Technology

| 0.48% | O: -6.86% H: 6.89% C: 4.6%
positive trial results

---

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Published: 2024-04-18 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K |

| -15.0% | O: -0.63% H: 1.89% C: -4.4%
neurology presentation readout positive topline meeting

---

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.87 -0.29% -0.29% 630K |

Finance

| 1.02% | O: 0.78% H: 0.0% C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living

---

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8367 -1.31% -1.33% 55K |

Manufacturing

| -27.97% | O: -12.71% H: 0.97% C: -24.27%
t-cell positive topline trial therapeutics results

---

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.296 -6.03% -6.42% 24K |

Health Technology

| -17.44% | O: 3.2% H: 0.0% C: -0.28%
qn-302 association positive cancer research meeting therapeutics

---

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K |

Health Technology

| -7.65% | O: 2.19% H: 6.15% C: 5.35%
metabolic positive for meeting hypertension therapeutics study

---

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
TARA | $2.81 -6.33% -6.76% 420K |

Health Technology

| -25.37% | O: 16.92% H: 11.06% C: -22.77%
tara-002 positive program therapeutics

---

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.43 0.29% 0.29% 650K |

Manufacturing

| -28.3% | O: 8.39% H: 2.71% C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced

---

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6199 -2.99% -3.08% 180K |

Health Care and Social Assistan...

| -13.53% | O: 1.34% H: 0.0% C: -4.21%
bt-600 positive trial therapeutics results platform

---

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $6.03 2.03% 1.99% 670K |

| 269.38% | O: 26.87% H: 276.85% C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics

---

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K |

Health Technology

| -8.52% | O: -2.27% H: 0.0% C: 0.0%
positive treatment results study

---

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ALGS | $0.8204 -0.39% -0.39% 640K |

Health Technology

| -19.61% | O: -1.96% H: 0.0% C: -2.1%
alg-0550 alg-000184 positive therapeutics

---

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
ATXS | $9.02 -6.43% -6.87% 660K |

Manufacturing

| -36.29% | O: 10.71% H: 0.9% C: -11.94%
star-0215 positive trial therapeutics results

---

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Published: 2024-03-22 (Crawled : 15:30) - globenewswire.com
ESPR | $2.115 1.2% 1.18% 5.4M |

Health Technology

| -0.95% | O: 0.0% H: 13.74% C: 8.53%
chmp positive hypercholesterolemia cardiovascular

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---